Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / GRAIL faces securities fraud lawsuit
Regulatory class action lawsuit

GRAIL faces securities fraud lawsuit

Analysis based on 6 articles · First reported Jun 08, 2026 · Last updated Jun 11, 2026

Sentiment
-40
Attention
3
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The class action lawsuit against Illumina — Holy Grail directly impacts its stock price and investor confidence due to allegations of securities fraud. For Rosen Law Firm, it represents a business opportunity and potential for increased revenue through contingency fees.

Biotechnology Legal Services
Event Summary

Rosen Law Firm has announced a class action lawsuit against Illumina — Holy Grail, a publicly traded company, on behalf of investors who purchased its common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that Illumina — Holy Grail made materially false and misleading statements and concealed adverse facts regarding the true state of its NHS-Galleri trial results. Specifically, the complaint states that the trial's three-year follow-up period was insufficient to demonstrate a reduction in Stage III-IV cancers, and Illumina — Holy Grail allegedly refused to provide detailed top-line results, potentially hiding negative trendlines. Investors are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026. Lawrence Rosen and Philip Kim are key contacts at Rosen Law Firm for this action.

Key Actions
100 Rosen Law Firm announced class action lawsuit Illumina — Holy Grail
100 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit Illumina — Holy Grail
100 Robbins Geller Rudman & Dowd LLP filed class action lawsuit Illumina — Holy Grail
100 Robbins LLP filed class action lawsuit Illumina — Holy Grail
90 Illumina — Holy Grail made misleading statements
89 Illumina — Holy Grail announced trial endpoint not observed
Entities Involved
subs
Illumina — Holy Grail
Illumina — Holy Grail is the defendant in a class action lawsuit alleging securities fraud due to misleading statements about its NHS-Galleri trial results. This event negatively impacts Illumina — Holy Grail's reputation and potentially its stock price.
Importance 100 Sentiment -60
priv
Rosen Law Firm
Rosen Law Firm is initiating and representing investors in the class action lawsuit against Illumina — Holy Grail, seeking compensation for alleged damages. This event enhances the firm's business and reputation.
Importance 80 Sentiment 50
per
Lawrence Rosen
Lawrence Rosen is a founding partner of Rosen Law Firm, involved in the class action lawsuit against Illumina — Holy Grail. His involvement highlights the firm's leadership.
Importance 30 Sentiment 40
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm, providing contact information for investors to join the Illumina — Holy Grail class action. His role is to facilitate investor participation.
Importance 30 Sentiment 40
govactor
United Kingdom — National Health Service
The United Kingdom — National Health Service is associated with the NHS-Galleri trial, which is central to the allegations against Illumina — Holy Grail. The trial's results are the basis of the lawsuit.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.